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The concept of amalaria vaccine has sparked great interest for decades; however, the challenge is proving to
be a difficult one. Immune dysregulation by Plasmodium and the ability of the parasite to mutate critical
epitopes in surface antigens have proved to be strong defense weapons. This has led to reconsideration
of polyvalent and whole parasite strategies and ways to enhance cellular immunity to malaria that may be
more likely to target conserved antigens and an expanded repertoire of antigens. These and other concepts
will be discussed in this review.Introduction
Malaria parasite infections are responsible for the loss of more
young lives than any other infection. They are caused by
species of the Plasmodia parasite that have very complex life
cycles involving various species of female Anopheline mosqui-
toes as primary hosts and vectors and a mammalian host. The
life cycle of Plasmodium in humans (Figure 1) commences with
the injection of sporozoites that then travel via the blood or
lymphatics. They engage the immune system by mechanisms
that are still not properly understood, but those that enter the
liver and invade hepatocytes can continue the life cycle by
developing into merozoites after a period of shizogony of 5–6
days. Typically, only a few hepatocytes may be invaded by
sporozoites in the first 30 min or so after mosquito bite, but
each invaded hepatocyte is capable of developing into approx-
imately 30,000 merozoites, which will then rupture from the liver
cell to commence the blood stage of the life cycle. Once in the
blood, a single merozoite can invade a red blood cell by using
various merozoite surface and micronemal proteins to engage
and then draw the merozoite inside the erythrocyte. Under-
standing the precise molecular mechanisms responsible for
hepatocyte entry and egress and red cell invasion is critical
to developing new approaches to both vaccine and drug
design.
Five species of Plasmodium are infectious for humans:
P. falciparum, P. vivax, P. malariae, P. ovale, and P. knowlesi,
recently identified as zoonotic (Cox-Singh et al., 2008). P. falci-
parum is responsible for the majority of malaria-induced deaths
andmost of themorbidity associated with malaria and has there-
fore been the focus of most research. The disease caused by
P. vivaxwas thought to be clinically less severe than that associ-
ated with P. falciparum and rarely lethal, but recent studies in
South East Asia have shown that approximately 25% of patients
with severe malaria have P. vivaxmonoinfection, andmulti-drug-
resistant vivax has been identified (Tjitra et al., 2008; Price et al.,
2009). Thus, substantial efforts are now being directed toward
P. vivax. In most areas where malaria is endemic, two or more
human plasmodial species coexist and it is becoming increas-
ingly apparent that the different Plasmodium parasites coinfect-
ing an individual interact with each other and exert cross-speciesregulatory effects (Snounou, 2004). Eliminating one species may
have potentially severe clinical consequences resulting from
a rebound effect or increase in prevalence of a parasite previ-
ously kept in check (Bruce and Day, 2002).
The Scientific Rationale for Developing
a Malaria Vaccine
Although it is self-evident that there is a great need for a vaccine
to curb the enormous mortality and morbidity associated with
malaria, it is important to discuss the various scientific rationales
for how a vaccine might be constructed. Before 1983, the year
when the first publications for cloningmalaria antigens appeared
(Ellis et al., 1983; Kemp et al., 1983), there had been much liter-
ature demonstrating that it was possible to induce immunity to
malaria in rodents, monkeys, or humans (as defined by complete
protection from sporozoite challenge or reduced blood-stage
parasite density) after exposure to live, irradiated, or killed organ-
isms (Nussenzweig et al., 1967; Cox, 1970; Clyde et al., 1973;
Siddiqui et al., 1978; McColm and Dalton, 1983; Collins and
Jeffery, 1999). These and other studies have informed the field
about possible mechanisms of immunity (Wipasa and Riley,
2007; Langhorne et al., 2008).
The ability to grow P. falciparum in vitro (Trager and Jensen,
1976) provided an added impetus to the quest for a blood-stage
vaccine derived fromwhole organisms. Only recently has it been
possible to think similarly of the ability to produce a sporozoite
vaccine based on organisms taken from laboratory mosquitoes
fed on cultured gametocytes (Hoffman et al., 2010). However,
the rationale for developing a malaria vaccine from whole organ-
isms was severely questioned when in 1983 reports were
published describing the ability to clone antigens, leading
quickly to a recombinant sporozoite protein vaccine trial (Ballou
et al., 1987) and then to vaccine trials based on recombinant
blood-stage antigens. These trials have been reviewed exten-
sively (e.g., Chattopadhyay and Kumar, 2009). Although the
immunological issues relevant to some of these vaccine candi-
dates will be discussed below, there is a major philosophical
question of how it would be possible to effectively vaccinate
naive individuals by exposing them to antigens to which they
would naturally be exposed to as a result of malaria infectionImmunity 33, October 29, 2010 ª2010 Elsevier Inc. 555
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Figure 1. Life Cycle of the Plasmodium spp.
Parasite in Humans
Sporozoites are injected into the human dermis
through the bite of an infected Anopheles
mosquito. After inoculation, sporozoites migrate
to liver cells to establish the first intracellular repli-
cative stage. The sporozoite and hepatic stages of
the parasite life cycle are collectively referred to as
the pre-erythrocytic stage. Merozoites generated
from this exoerythrocytic phase then invade eryth-
rocytes, and it is during this erythrocytic stage that
the clinical symptoms of malaria occur. The life
cycle is completed when sexual stages (gameto-
cytes) are ingested by a mosquito. The immune
mediators implicated at the different stages of
the life cycle are shown.
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years. Put differently, what is fundamentally different about
immune responses that develop after immunization with
Plasmodium proteins and those that develop after natural infec-
tion and exposure to the same proteins? Clearly, to be effective,
a vaccine must induce a response that is either qualitatively
and/or quantitatively different from the immune response that
follows infection. It is thus important to understand thoroughly
the immune response that follows natural infection.
Although there are many reviews on the nature of natural
immunity to malaria, something that develops slowly and only
over a number of years (Baird, 1998; Doolan et al., 2009), two
studies (one relevant to blood-stage immunity and the other to
sporozoite-liver-stage immunity) underline the challenges and
the nature of the immunity to Plasmodium spp. parasites.
With respect to blood-stage immunity, a study by Miller et al.
(1994) with data describing the parasite densities in an individual
who contracted malaria was very instructive. Data in this study
trace the parasite density in the blood of an individual over
a 9 month period and demonstrate that the individual suffers
from sequential peaks in parasite density over that time frame.
We now understand that the peaks represent sequential variants
that develop and that each express a unique antigen of the
P. falciparum Erythrocyte Membrane Protein 1 (PfEMP1) variant
surface antigen family on the surface of the infected red blood
cell (Baruch et al., 1995). Antibodies develop to a particular
variant PfEMP1 and then reduce the parasite burden until a novel
PfEMP1 is expressed and the parasite density then increases
again. Clearly, making a vaccine with recombinant PfEMP1
represents a substantial challenge. However, it is worth noting
that the height of the sequential peaks progressively diminishes
over the 9 month period. The mechanisms responsible for this
represent an important area of research that may lead to new
insights into vaccine development.556 Immunity 33, October 29, 2010 ª2010 Elsevier Inc.With respect to sporozoite-liver immu-
nity, circumstantial evidence suggests
that natural sterilizing immunity to sporo-
zoites does not develop. In one study,
adults living in a malaria-endemic area
of East Africa were administered drugs
to clear Plasmodium parasites and were
then followed for the acquisition of para-
sites in their blood. During a 3 monthperiod, more than 70% of individuals developed malaria and
the trend analysis suggested that all would develop malaria if
further followed (Hoffman et al., 1987). In other treatment reinfec-
tion studies, the reinfection rate (incidence density of primary
parasitemia) was virtually identical in cohorts of location-
matched infants (6–24 months old) and adults resident in
northern Ghana (Owusu-Agyei et al., 2001; Baird et al., 2002).
Although there may be a few subjects who do not develop para-
sitemia in such studies (Owusu-Agyei et al., 2001; Baird et al.,
2002), suggesting that in them immunity to the pre-erythrocytic
stage and/or blood-stage parasite can develop after field expo-
sure, the vast majority do become parasitemic, showing that
natural sporozoite immunity (which if effective would prevent
all individuals from acquiring any blood-stage malaria infection)
is almost always incomplete. Subsequent work suggested that
the lack of sporozoite immunity was due, at least in part, to poly-
morphisms within a major sporozoite surface antigen, the cir-
cumsporozoite protein (CSP), and to poor immunogenicity
(Good et al., 1988a, 1988b).
These issues of lack of natural immunity and antigenic varia-
tion or polymorphism will be recurring themes throughout this
review. The review will not focus on sexual-stage immunity,
although this is an extremely interesting approach to vaccine
development, which has recently been reviewed (Coutinho-
Abreu and Ramalho-Ortigao, 2010); rather, the emphasis will
be on sporozoite-liver-stage immunity, blood-stage immunity,
and vaccine approaches to these different stages.
Immunological Considerations: Sporozoite-Liver-Stage
Immunity
Infection of the mammalian host by Plasmodium triggers an
immune response that is hierarchically organized by the first
line defense involving the innate immune system followed by
the adaptive immune response involving cognate immune
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Figure 2. Induction of Liver-Stage Immunity
(A) Mosquitoes inject small numbers of Plasmodium sporozoites into the skin.
(B) Some of these parasites associate with dendritic cells in the draining lymph
nodes. These dendritic cells can present Plasmodium sporozoite antigens to
naive T cells, priming the T cells to recognize the parasites. These activated
T cells enter the circulation and traffic to the liver.
(C) Activated T cells, primed either at the draining lymph node or in the liver,
can destroy the infected hepatocytes that display parasite antigen-MHC
complexes on their surface, reducing liver-stage parasite load.
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cycle involving both extracellular (sporozoites and merozoites)
and intracellular (liver) stages (Figure 1), both T cell and antibody
responses play a role in protective immunity to malaria. The roles
of CD8+ T cells and CD4+ T cells in liver-stage immunity have
been reviewed elsewhere (Doolan and Martinez-Alier, 2006;
Overstreet et al., 2008; Tsuji, 2010), as has the role of CD4+
T cells and B cells for blood-stage immunity (Stevenson and
Riley, 2004; Wipasa and Riley, 2007; Langhorne et al., 2008;
Pierce, 2009) and the topic of memory (Wykes and Good,
2006; Cockburn and Zavala, 2007; Minigo et al., 2007). Accord-
ingly, herein, we focus more on recent immunological insights
with implications for rational vaccine design.
Early reports in murine models established that T cells were
important for pre-erythrocytic (sporozoite-liver) stage immunity,
with studies showing that CD8+ T cells were critical and that the
T cell responses were directed primary at the intrahepatic para-
site (Figure 2; Schofield et al., 1987; Weiss et al., 1988; Doolan
and Martinez-Alier, 2006; Overstreet et al., 2008; Tsuji, 2010).
The CSP was shown to be a target of CD8+ T cells and a minimal
epitope was defined (Kumar et al., 1988). However, little was
known about how sporozoite- and liver-stage antigens are pro-
cessed and presented to T cells. Recent studies in mice have
shed some light on the basic biology of Plasmodium and on
the question of how and where T cells are primed in vivo for
sporozoite-induced immunity (Vaughan et al., 2008; Ejigiri andSinnis, 2009; Coppens et al., 2010). During a blood meal,
Plasmodium-infected mosquitoes deposit sporozoites in the
skin, many of which eventually exit to the bloodstream and infect
hepatocytes. However, sporozoites can remain in the skin for
at least 6 hr after mosquito inoculation (Yamauchi et al., 2007),
and it is possible that retention of parasites in the dermis may
affect the site of antigen presentation as well as the locality
and type of responses initiated. Skin-derived CD103+ dendritic
cells have been identified as a migratory subset with a key role
in cross-presentation of viral antigens to naive CD8+ T cells (Bed-
oui et al., 2009), and a growing body of data highlight the number
of distinct dendritic cell subsets and the influence of anatomic
environment on antigen-presenting capacity and resultant
immune responses (Chung et al., 2007; Heath and Carbone,
2009). Approximately one-third of the sporozoites leave the
skin injection site and are drained to the regional lymph nodes
where they can be internalized by dendritic cells (Amino et al.,
2006). After invading the liver, each sporozoite undergoes exten-
sive replication inside a parasitophorous vacuole surrounded
by a membrane, and parasite proteins with an N-terminus Plas-
modium export element motif may be selectively transported
across the vacuolar membrane into the hepatocyte cytoplasm
(Singh et al., 2007). A subset of the proteins, including the
CSP, use a nuclear localization signal to enter the nucleus, where
they influence the expression of thousands of host cell genes to
create a favorable niche for parasite growth (Singh et al., 2007).
In the liver, antigens need to be processed and presented on the
surface of the infected hepatocytes in the context of class I or
class II MHC molecules for recognition by CD8+ or CD4+
T cells, respectively. The specific antigen-presenting cells and
the antigen processing and presentation pathways involved in
immunity to malaria are poorly understood, but recent studies
have been informative.
Transgenic mice generated with a T cell receptor (TCR)
specific for an epitope of the P. yoelii CSP (Sano et al., 2001;
Overstreet et al., 2008) have proved a useful tool for dissecting
CD8+ T cell immunity, although it should be recognized that
CSP may not be exemplary for other antigens, so conclusions
from studies in this model may not necessarily be universally
applicable. With this model, it was shown that after an infectious
mosquito bite, some sporozoite antigens, including CSP, remain
in the skin where CSP-specific CD8+ T cells are primed by
dendritic cells that reside in skin-draining lymph nodes; the
activated CD8+ T cells then migrate to the liver where they
eliminate parasitized hepatocytes during subsequent infections
(Chakravarty et al., 2007). The effector cells recognized sporo-
zoite antigens on parenchymal cells (presumably parasitized
hepatocytes) and not on bone marrow-derived antigen-present-
ing cells such as dendritic cells.
These data suggested that dendritic cells cross-present
sporozoite antigens to naive T cells in the draining lymph nodes.
However, this mechanism would not apply to those antigens
expressed by the liver-stage parasite but not the sporozoite
(Good and Doolan, 2007) and liver-stage-specific antigens are
known to be targets of CD8+ T cell-mediated protection against
sporozoite challenge (Doolan et al., 1996; Overstreet et al., 2008;
Tsuji, 2010). Rather, T cells specific for liver-stage antigens as
well as sporozoite antigens (because sporozoites can invade
the hepatocyte within minutes of infection) are probably inducedImmunity 33, October 29, 2010 ª2010 Elsevier Inc. 557
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those antigens and presented by resident antigen-presenting
cells (Good and Doolan, 2007).
That antigen can be presented to CD8+ T cells in the hepato-
cyte is established. T cell-dependent protective immunity
against P. yoelii and P. berghei sporozoite infection could be
induced by intrasplenic adoptive transfer of a small number of
parasite-infected hepatocytes (Renia et al., 1994). In addition,
both infected and traversed primary hepatocytes exposed to
P. berghei sporozoites in vitro could process and present CSP
to specific CD8+ T cells; the processing was largely dependent
on proteasomes and to a lesser extent on aspartic proteases
(Bongfen et al., 2007, 2008). It was also demonstrated in vivo
after intravenous immunization with irradiated P. berghei
sporozoites that liver-resident dendritic cells, particularly those
that express CD8a (a subset of conventional CD11c+ dendritic
cells), can present parasite antigen to hepatic CD8+ T cells
(Jobe et al., 2009). CD8a + dendritic cells are considered the
major inducers of CD8+ T cells in viral and intracellular bacterial
systems (Belz et al., 2004, 2005).
To what extent hepatocytes contribute as antigen-presenting
cells in vivo, what other tissue-specific antigen-presenting cell
subsets may be involved in processing and presenting exo-
erythrocytic antigen, and whether antigen-presentation path-
ways in Plasmodium infection differ to those of other proto-
zoan, bacterial, or viral pathogens remains to be established.
It also remains to be determined whether human Plasmodium
parasites behave similarly to rodent parasites with regard
to cell biology, host-parasite interactions, and induction of
immunity.
Antigen Persistence
One question with obvious implications for vaccine design is
whether antigen persistence is required for induction of T cell
responses against exo-erythrocytic-stage parasites, noting
that irradiated sporozoites are incapable of replication and do
not differentiate beyond early liver stages (Silvie et al., 2002).
A number of studies have attempted to address this by using
primaquine to eliminate the intrahepatic parasite, but those
results have not been conclusive (Doolan and Martinez-Alier,
2006; Putrianti et al., 2009; Mikolajczak et al., 2010). It should
be noted that such studies only provide evidence for the need
(or not) for parasite persistence and provide no information on
antigen persistence. This was partly addressed recently by
Zavala and colleagues who showed, via adoptive transfer
studies, that CSP antigen was detected in lymphoid organs for
more than 8 weeks after irradiated sporozoite immunization
and that this persistence was dependent on the presence of
CD11c+ cells. They further established that prolonged antigen
presentation was required for optimal expansion and effector
function of the CSP-specific CD8+ T cell responses (Cockburn
et al., 2010). Nevertheless, parasite persistence may be required
for complete protection even though antigen and cellular
immune responses may persist after parasite clearance. These
data are consistent with observations in the field where individ-
uals lose immunity to malaria when they move to a nonendemic
region (Langhorne et al., 2008) and where T cell responses to
P. vivax (which has persisting hypnozoite forms) but not
P. falciparum (which does not) persist for several years beyond
infection (Zevering et al., 1994).558 Immunity 33, October 29, 2010 ª2010 Elsevier Inc.Earlier studies by the same group showed that the magnitude
of the CD8+ T cell responses correlated with the primary clonal
burst and that increasing the time of antigen presentation by
daily immunizations did not enhance the magnitude of this
response (Hafalla et al., 2002). These and other data (Doolan
and Martinez-Alier, 2006) suggest that the optimal vaccination
strategy for CD8+ T cell immunity is the delivery of a maximal
amount of antigen in a vaccine dose.
Threshold of Immune Response
Regarding effector function, we have previously described
a threshold of immune response concept, whereby the protec-
tive immunity induced by whole organism immunization reflects
the accumulation of small responses to a large number of
antigens; alternatively, a single antigen with one or more target
epitopes could be sufficient to generate a protective immune
response if appropriately presented to the immune system
(Doolan and Hoffman, 1997). Harty and colleagues have vali-
dated this concept experimentally. By using a model of
P. berghei CSP-specific memory CD8+ T cell generation, they
defined a threshold frequency of memory CD8+ T cells in the
blood that predicts long-term sterilizing immunity against liver-
stage infection (Schmidt et al., 2008). Extremely high frequencies
of sporozoite-induced memory CD8+ T cells were required for
sterilizing anti-Plasmodial immunity and this number greatly
exceeds the number of memory CD8+ T cells required for resis-
tance to other pathogens. Diversifying the targeted antigens
through whole-sporozoite immunization only minimally, if at all,
reduced the numerical requirements for memory CD8+
T cell-mediated protection as compared to a protective subunit
vaccine that elicits a CD8+ T cell responses to a single epitope
(Schmidt et al., 2010). These data highlight the need for whole
organism or subunit vaccines against malaria to induce very
potent CD8+ T cell responses. A large number of studies in
animal models with subunit vaccines based on a single antigen
suggest that sterile protection requires induction of very potent
T cell responses that are currently achievable only with heterol-
ogous prime-boost regimes (Hill et al., 2010).
Immunological Considerations: Blood-Stage Immunity
Blood-stage infection commences when an infected hepatocyte
ruptures, liberating as many as 30,000 infectious merozoites into
the circulation. These may be released as a ‘‘raft’’ of merosomes
that may travel to the lung before further dissemination into the
blood (Baer et al., 2007). In the blood, a single merozoite invades
an erythrocyte, and, in the case of the two most common
Plasmodia (P. falciparum andP. vivax), they undergo a 48 hr repli-
cative cycle resulting in approximately 16 new merozoites
rupturing from each erythrocyte. Thus, there is no draining lymph
node to initiate an immune response to the blood stages, but the
spleen plays a critical role as suggested from studies in humans
(e.g., Guazzi and Grazi, 1963), monkeys (e.g., Cohen and Mitch-
ell, 1978), and rodents (e.g., Kumar et al., 1989). Histological
studies have shown that the architecture of the spleen alters after
infection (Weiss et al., 1986), which may be crucial to immunity.
Various cell types in the spleen have been implicated in immu-
nity. Marginal metallophillic macrophages and marginal zone
macrophages are thought to be important in the initiation of
anti-Plasmodium immunity, and CD8+ T cells and other immune
mechanisms, induced as a result of malaria infection, can
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Figure 3. Linking Innate and Adaptive
Immunity to Blood-Stage Malaria
Possible regulation of adaptive immunity to blood-
stage malaria by cytokines produced by cells of
the innate immune response. In response to para-
site ligands recognized by pattern-recognition
receptors (PRRs), such as Toll-like receptors
(TLRs) and CD36, or inflammatory cytokines,
such as interferon-g (IFN-g), dendritic cells (DCs)
mature and migrate to the spleen—the primary
site of immune responses against blood-stage
Plasmodium parasites. Maturation of DCs is asso-
ciated with the upregulation of expression of MHC
class II molecules, CD40, CD80, CD86, and adhe-
sion molecules and the production of cytokines
including interleukin-12 (IL-12). IL-12 activates
natural killer (NK) cells to produce IFN-g and
induces the differentiation of T helper 1 (Th1) cells.
The production of cytokines, particularly IFN-g, by
NK cells results in DC maturation and enhances
the effect of parasite-derived maturation stimuli,
facilitating the clonal expansion of antigen-specific naive CD4+ T cells. IL-2 produced by antigen-specific Th1 cells further activates NK cells to produce IFN-
g, which induces DCmaturation and activatesmacrophages, further amplifying the adaptive immune response. Cytokines such as IL-10 and transforming growth
factor-b (TGF-b) negatively regulate both innate and adaptive responses. NO, nitric oxide; TCR, T cell receptor; TNF, tumor-necrosis factor.
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T cells (functioning as either helpers for an antibody response
or as effectors), B cells, and NK cells are all known to play critical
roles, and their interactions have been reviewed (Figure 3; e.g.,
Stevenson and Riley, 2004; Langhorne et al., 2008). Although
splenic transfer studies, whereby an immune spleen is trans-
planted into a naive rat, have shown that the spleen alone can
control infection very efficiently, it has been also shown that
nonsplenic tissue can contribute to control, although not as
effectively (Favila-Castillo et al., 1996).
During natural infection, antibodies are generated that recog-
nize both merozoite surface antigens and erythrocyte mem-
brane-associated antigens, and these have been shown to
have agglutinating or growth inhibitory properties in vitro.
Passive transfer of immune sera can control parasite growth
effectively, providing that the animals have a functioning immune
system (Hirunpetcharat et al., 1999). However, some studies in
both humans (Dorfman et al., 2005) and mice (M. Wykes and
M.F.G. et al., unpublished data) show that memory B cells are
either poorly induced to develop or are short lived as a result
of infection. However, in one study, a single infection with
P. chabaudi could induce memory B cells and long-lived plasma
cells (Ndungu et al., 2009). Recent studies in Mali showed that
memory B cells and antibodies increased gradually over many
years and were dependent on cumulative exposure to malaria,
not on age (Crompton et al., 2010; Weiss et al., 2010).
It is also known that CD4+ T cells can effectively control para-
site growth. This has been elegantly shown by studies in which B
cell-deficient mice could be successfully immunized by infection
and drug treatment (Grun and Weidanz, 1983), by studies
showing that CD4+ T cell clones can adoptively transfer protec-
tion (Brake et al., 1986; Amante and Good, 1997), and by the
ability of human T cell clones (CD4+ and CD8+) to inhibit parasite
growth in vitro (Fell et al., 1994). Other studies have also sug-
gested that human CD4+ and CD8+ T cells can control parasite
growth in vivo (Pombo et al., 2002; Roestenberg et al., 2009).
T cell-mediated killing is thought to occur in the spleen by the
nonspecific action of small inflammatory molecules, such as
nitric oxide (reviewed in Wykes and Good, 2009).Immune Evasion and Immune Modulation
In spite of these immune processes and mechanisms, the para-
site is adept at evading immunity by a variety of mechanisms
that allow it to persist in the host. Possible mechanisms of inter-
ference in T cell and B cell activation and the generation of immu-
nological memory by Plasmodium have been summarized
elsewhere (Langhorne et al., 2008; Casares and Richie, 2009).
Of particular relevance to vaccine development are the ability
of the parasite to either (1) interfere with presentation and/or
processing (Sponaas et al., 2006) and cause apoptosis and
deletion of T cells and other effector cells (Hirunpetcharat and
Good, 1998; Kemp et al., 2002; Xu et al., 2002) or (2) mutate the
sequence of epitopes critical for T or B cell recognition (Good
et al., 1988a; Barry et al., 2009). Additionally, because malaria
is a chronic infection, it is possible that T and B cell exhaustion
may contribute to the suboptimal host immunity that is inade-
quate to control the parasite. Recent data from a longitudinal
study in Mali has shown that exhausted B cells comprise 20%–
60% of that circulating B cell pool as compared with 1%–2% of
the B cell pool in people from nonendemic areas (Pierce, 2009).
Leading Vaccine Approaches
Data in animal models support the concept of developing
a malaria vaccine that can improve on natural immunity by either
(1) inducing more robust and potent immune responses against
a selected panel of antigens recognized as immunodominant
in the context of natural infection, or (2) inducing a broader
immune response against a large number of parasite antigens.
For the former, efforts have been directed at identifying and
refining vaccine platforms capable of inducing robust immune
responses. For the latter, strategies include the renewed interest
in whole parasite vaccines, including the irradiated sporozoite
vaccine (Hoffman et al., 2010), asexual blood-stage vaccine
(Good, 2005; Pinzon-Charry et al., 2010), or genetically attenu-
ated parasite vaccines (Vaughan et al., 2010). Additionally, the
recent availability of genomic, proteomic, and transcriptomic
data sets for the key human, nonhuman primate, and rodent
malarias has facilitated immunomic-based approaches to iden-
tify promising vaccine candidate antigens (Doolan, 2010).Immunity 33, October 29, 2010 ª2010 Elsevier Inc. 559
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showed a reduction but not complete abrogation of protection
induced by immunization with irradiated P. yoelii sporozoites
(Kumar et al., 2006), and mice immunized with irradiated
P. berghei sporozoites were completely protected against chal-
lenge with transgenic P. berghei parasites expressing the
P. falciparum CSP in the absence of functional responses
against the CSP (Gruner et al., 2007). In humans, we have
demonstrated that irradiated sporozoite-induced T cells and
antibodies recognized a broad panel of antigens, the majority
of them not previously described, and that sporozoite-induced
responses against well-characterized pre-erythrocytic stage
antigens did not discriminate protected from unprotected
subjects (Doolan et al., 2003). Recently, a broad antibody
response to multiple antigens has been associated with protec-
tion from clinical malaria in the field (Osier et al., 2008; Crompton
et al., 2010). Collectively, these data support the development of
vaccines based onmore than one target antigen. Identification of
the range of key antigens targeted by protective immune
responses is a challenge, but may potentially reap great rewards
in terms of rational vaccine design (Doolan, 2010; Sette and
Rappuoli, 2010). A whole parasite strategy is the ultimate
example of such a vaccine.
Recombinant Protein Subunit Vaccines
Most malaria vaccine efforts to date have focused on the use of
protein-in-adjuvant formulations, primarily for the induction of
antibody responses against blood-stage antigens. Many target
antigens expressed on the surface of merozoites have been
defined, including MSP1, AMA1, and MSP2 among the leading
candidates, and studies have demonstrated that antibodies to
these proteins, if induced in high titer, can confer protection
against homologous parasite challenge (e.g., Singh et al.,
2006). However, thus far, no recombinant protein-in-adjuvant
formulations have proved sufficiently efficacious to warrant
additional testing (Richards and Beeson, 2009). One obstacle
is that the production of high-quality and correctly folded
recombinant proteins is difficult for Plasmodium (Angov et al.,
2008). The lack of availability of potent adjuvants suitable for
human use (especially those that induce cellular immunity) has
also proved to be a substantial limitation (Coler et al., 2009;
Reed et al., 2009).
The enormous resources devoted to novel adjuvant systems
(AS) by GlaxoSmithKline and partners to improve the efficacy
of the leading malaria vaccine candidate, RTS,S, has recently
reaped some reward. After more than 20 years of research and
development, it was demonstrated that RTS,S delayed time to
new infection and reduced episodes of severe malaria over
6 months in African children; 30%–50% protection against
both infection and clinical disease was sustained for at least
18 months (Cohen et al., 2010). Phase 3 testing of the
RTS,S/AS01E vaccine (a liposome-based adjuvant system) is
now underway. The mechanism of protection induced by
RTS,S is unknown but may be mediated by antibodies directed
against the P. falciparum CSP, with a contribution of CD4+ IFN-g
secreting T cell responses. However, the role of T cells in protec-
tion is unclear because the T cell epitope region of RTS,S is
highly polymorphic (Good et al., 1988a, 1988b) and RTS,S
does not contain the complete CSP sequence and is therefore
lacking a number of well-defined T cell epitopes.560 Immunity 33, October 29, 2010 ª2010 Elsevier Inc.Other studies of liver-stage or blood-stage recombinant
protein vaccine candidates using the most promising adjuvant
formulations, including the GSK AS adjuvants, have been disap-
pointing. Examples include recent failures in phase 2a experi-
mental challenge studies of the liver-stage vaccine candidate
LSA1 despite induction of high antibody titers and CD4+ T cell
responses (Cummings et al., 2009), and failures in phase 2b field
trials of the leading asexual blood-stage candidates MSP1 and
AMA1 (Malkin et al., 2007; Ogutu et al., 2009; Sagara et al.,
2009; Spring et al., 2009) despite induction of antibody
responses that conferred very high growth inhibitory activity
(GIA) in vitro (Spring et al., 2009). This standardized in vitro assay
is currently considered the best in vitro assay of the biological
function of vaccine-induced antibodies (Miura et al., 2009) and
thus the most relevant assay to screen potential blood-stage
vaccine candidates prior to clinical development. However,
polymorphism of parasite surface antigens presents a major
impediment to the development of natural immunity to malaria,
because natural challenge will present the vaccinee with novel
haplotypes not represent in the vaccine (Duan et al., 2008).
Thus, although inducing a high antibody titer to define target
antigen in humans is a substantial challenge, a far greater
challenge with these antigens is to induce an immune response
that recognizes all parasite strains. Although this difficulty has
been observed in experimental immunization and challenge
studies in humans (Genton et al., 2002; Takala et al., 2007) and
animals (Kennedy et al., 2002), the magnitude of the problem is
best described in a study that looked at the number of nonsynon-
ymous haplotypes that are known to date for 12 leading vaccine
candidates (Barry et al., 2009). For some antigens, several
hundred haplotypes exist, suggesting that it will be impossible
to develop a vaccine with these antigens unless a nonpolymor-
phic epitope that induces protection can be defined.
DNA and Vectored Subunit Vaccines
For the induction of T cell responses, a number of distinct
vaccine platforms have been evaluated, including synthetic
peptides, plasmid DNA vaccines, and viral vectored vaccine
platforms (Bruder et al., 2010a; Hill et al., 2010; Limbach and
Richie, 2009; Liu, 2010; Nardin, 2010; Olugbile et al., 2010). Early
studies used these platforms alone in single dose or homologous
boost immunization strategies. Plasmid DNA vaccines proved to
be very effective in inducing CD8+ T cell responses and confer-
ring protection in animal models, but were not effective in
humans (Wang et al., 1998; Doolan and Hoffman, 2001; Epstein
et al., 2002; Richie, 2006). Efforts were then directed to viral-
vectored vaccines including recombinant vaccinia, modified
virus Ankara, fowlpox, adenovirus (multiple strains and sero-
types), or viral replicon particles that have been used in homolo-
gous or heterologous immunization regimens with promising
results (Bruder et al., 2010b; Hill et al., 2010).
Viral-vectored vaccines were initially considered only for the
induction of strong cellular immune responses against the trans-
gene of interest because of their ability to induce potent CD8+
T cell responses (Liu, 2010). Subsequent studies showed that
viral vectors could be optimized to induce both T cell and
antibody responses. For example, a PfAMA1 adenovirus sero-
type 5 vaccine optimized for surface antigen localization and
glycosylation induced unprecedented amounts of biologically
active antibodies in rabbits (as indicated by parasite GIA) that
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system including recombinant protein in adjuvant as well as
good CD8+ T cell responses (Bruder et al., 2010b). Those data
support the concept that tailored combinations of vaccine
platforms can achieve desired combinations of immune
responses. Other data in animal models suggested that superior
antibody responses with no reduction of T cell responses could
be induced if the recombinant adenovirus vaccine was adminis-
tered after a DNA prime (Bruder et al., 2010a) or subsequent to
a protein or adjuvant boost (Stewart et al., 2007). In mice, an
optimized PyMSP1-19 adenovirus (AdCh63) prime-MVA vector
boost regimen elicited antibody responses of similar potency
to those induced by multiple immunizations of recombinant
protein-in-adjuvant vaccines and protected against a virulent
blood-stage challenge in an antibody-dependent manner
(Draper et al., 2008). This heterologous viral vector immunization
regime also induced potent CD8+ T cell responses that reduced
the parasite burden at the liver stage (MSP1 is expressed in both
late liver and asexual blood stages) (Draper et al., 2009). To our
knowledge, this is the first report that protective multistage
immunity against liver- and blood-stage malaria can be induced
in an animal model by subunit vaccines based on a single target
antigen.
Whether vectored vaccines can induce CD4+ T cell capable of
controlling blood-stage parasitemia has not yet been reported
and, to date, no candidate vaccine designed to preferentially
induce T cell response against blood-stage malaria has been
evaluated in the clinic, despite observations in mice (Draper
et al., 2008, 2009) and humans (Pombo et al., 2002) for a role
of T helper 1 (Th1) cell response in blood-stage immunity.
Strategies to Induce a Different Type of Immune
Response
After natural infection, antibodies develop to the infecting strain;
however, these are largely ineffective in preventing subsequent
infection. Plasmodium infection does not induce a strong T cell
response, particularly in young children (Le Hesran et al.,
2006; D’Ombrain et al., 2008; Ssewanyana et al., 2008), and
there is evidence from human and murine studies that infection
leads to apoptosis of parasite-specific T cells, as already noted.
However, it is known from experimental studies that human
(Fell et al., 1994) and murine (Brake et al., 1986) T cells, if
induced, can control parasite growth in vivo and in vitro.
Because T cells can recognize intracellular antigens, many of
which will perform vital housework functions of the cell and
which would be deleterious to the organism if mutated, the
downregulation of cellular immunity after infection can be seen
as a vital mechanism to permit parasite survival and growth.
However, it is known that as immunity develops, individuals
living in endemic areas do have T cells in their peripheral blood
that can respond to Plasmodium. Whether this belated develop-
ment of a cellular immune response occurs after the acquisition
of immunity or whether the development of cellular immune
responses is responsible for the eventual acquisition of protec-
tion is not known. However, a study of semi-immune older chil-
dren in Papua New Guinea demonstrated that those whose
T cells produced the highest amount of IFN-g in vitro in response
to parasite stimulation were the least likely to suffer a high-
density parasite infection in the subsequent 6 month period
(D’Ombrain et al., 2008).An early study inmice suggested that T cells that were induced
after P. yoelii infection and drug cure were protective against not
only P. yoelii but also the other three rodent Plasmodium
species, P. berghei, P. vinckei, and P. chabaudi, as well
(Grun andWeidanz, 1983). This indicated that the target antigens
of protective T cells are highly conserved. In that study, the B
cell-antibody response of the mice was suppressed by treat-
ment of the mice from birth with mu antibody. Of interest, an
earlier study, in which the antibody response of mice was not
suppressed by mu antibody treatment, showed that mice immu-
nized against P. yoelii by infection and drug cure were not
immune to the other rodent Plasmodia (Cox, 1970). It thus
appears that if mice are forced to generate an adaptive immune
response via T cells alone, they respond to highly conserved
antigens, but if given the opportunity to respond by using B cells
and T cells, their immune response to Plasmodium is likely to
recognize epitopes unique to the immunizing species or strain.
The mechanism responsible for this alteration in the specificity
of the immune response is unknown, but it is tempting to spec-
ulate that the absence of B cells may downregulate the number
of follicular T cells (Fillatreau and Gray, 2003) and facilitate the
growth of Th1 cells that are known to function as effectors of
cell-mediated immunity (Langhorne et al., 1989).
A strategy for vaccine development that follows from this is to
thus define target antigens for protective T cells that are not
targets of antibody. To date, only one such antigen has been
defined (Makobongo et al., 2003). In this study, a proteomics
approach was used to define the purine salvage enzyme
HGXPRT as a target antigen of a protective T cell clone. Further-
more, immunization with recombinant P. falciparum HGXPRT
was able to protect mice against P. yoelii, demonstrating the
high degree of conservation of T cell target epitopes between
different species. One difficulty with using HGXPRT as a vaccine
for malaria will be the homology between HGXPRT and the
human homolog HGPRT, limiting the number of responders in
the population (D. Stanisic and M.F.G., unpublished data). This
has prompted us to define other strategies that would induce
a broad T cell response. Based on our observations that para-
sites in high density could cause apoptosis of parasite-specific
T cells (Hirunpetcharat and Good, 1998; Xu et al., 2002), we
asked whether parasites in ultra-low dose might induce potent
T cell responses. We determined that naive human volunteers
who had been exposed to a subpatent (i.e., low-dose) P. falcipa-
rum infection after deliberate infection with only 30 parasitized
red blood cells and then drug treated developed a very strong
T cell immune response in the complete absence of any
antibody. When challenged and then followed for 2 weeks, para-
sites did not grow in three of four individuals and grew more
slowly and remained subpatent in another (Pombo et al., 2002).
Although it cannot be excluded that residual drug may have
contributed to the apparent strong antiparasite immunity,
a follow-up study in P. chabaudi demonstrated that subpatent,
but not patent, infection with one strain (AS) led to very
strong cellular immunity and protection against not only AS but
CB strain parasites as well (Elliott et al., 2005). Roestenberg
et al. (2009) have shown that infection of naive human vol-
unteers with 15 infected mosquitoes under cover of chloroquine
chemoprophylaxis similarly led to cellular immune responses
and protection after subsequent challenge with infectedImmunity 33, October 29, 2010 ª2010 Elsevier Inc. 561
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protection was as a result of sporozoite-liver-stage immunity,
blood-stage immunity, or a combination, it is known that approx-
imately 1000 irradiated infected mosquitoes are required for
successful immunization (Hoffman et al., 2002), far more than
the 15 to which the volunteers in the study were exposed. It
thus seems more likely to us that immunity was the result of
a very low-dose blood-stage infection that would be the conse-
quence of mosquito-derived infection of volunteers receiving
chloroquine. The drug is able to kill the parasites in the blood
after release from the liver, but would have no effect on the liver
or sporozoite stages. The only way to prove that protection in the
Roestenberg experiment was either the result of sporozoite-liver
or blood-stage immune responses would be to challenge the
recipients with infected red blood cells.
To develop an ‘‘off the shelf’’ vaccine, we have asked whether
low doses of parasites killed by freeze-thawing could also induce
potent T cell responses. By using an adjuvant approach devel-
oped by Su et al. (2003), we have shown that 100–1000 killed
P. chabaudi-infected red cells mixed with CpG and Alum can
induce a protective T cell response in mice dependent on
CD4+ T cells, IFN-g, IL-12, and nitric oxide, but not dependent
on antibody (Pinzon-Charry et al., 2010). The target epitopes of
the protective T cells are clearly highly conserved; mice immu-
nized by this approach are protected against different strains
and indeed species of Plasmodium.
The rationale for this strategy is consistent with that outlined at
the start of this article. Strong T cell responses are not naturally
induced after Plasmodium infection and as such the target
epitopes do not come under selective pressure. Selective pres-
sure is further reduced by the nature of how T cells are thought to
kill parasites. Although T cells are activated specifically, they are
thought to kill nonspecifically in the spleen after activation of
macrophages and via soluble mediators such as nitric oxide.
This would reduce the selective pressure of any antiparasite
effect. The induction of strong T cell responses by vaccination
would thus ‘‘blind-side’’ the parasite, as seems to be the case.
Although this review has focused on immune aspects of
malaria vaccine design, we have stated that it is self-evident
that there is a need for a vaccine to curb malaria-associated
mortality and morbidity. Whether a vaccine can do more than
this and contribute to malaria eradication is a matter of
current debate. The call for malaria eradication has been made
(Roberts and Enserink, 2007) but it is our view that if that ideal
is to be achieved, then more than yet-to-be-developed vaccines
would be required. Improved public and primary health care,
mosquito control, and effective and affordable drug therapy
would all be required to play an important role along with effec-
tive vaccines. Similar sentiments have been expressed by others
(Plowe et al., 2009).
Conclusion
Malaria parasites can subvert immune responses and avoid
immune pressure, explaining in part the persistence of the para-
site in individuals and as a public health threat. Attempts to
prevent infection by inducing immunity after vaccination must
focus on novel aspects of immune control and target conserved
antigens. This review acknowledges only a fraction of the enor-
mous body of literature underpinning our understanding of562 Immunity 33, October 29, 2010 ª2010 Elsevier Inc.malaria immunity but attempts to draw together threads that
may instruct novel vaccine strategies. We eagerly await the
results of the RTS,S sporozoite vaccine now in Phase 3 clinical
trials, but suggest that other approaches, particularly those
involving whole parasites, are worthy of more consideration.
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